Markets
Corcept Stock Plunges 9%, Wiping Out $820 Million, After Earnings Report
The drugmaker kept its 2026 revenue forecast, and an FDA decision on relacorilant is due December 17.
Corcept Therapeutics (CORT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The drugmaker kept its 2026 revenue forecast, and an FDA decision on relacorilant is due December 17.
Earnings
The new endocrinology president put a number on the drug's potential as an FDA decision looms on December 17.
SEC Filings
Corcept's 10-Q turns a generic-competition warning into a stated fact and adds legal expenses to the causes of $164.4 million in quarterly SG&A.
Deals
Revenue rose 64% to $340.5 million, and the drugmaker held its $1.1 billion to $1.2 billion 2026 revenue forecast.